Novelion Therapeutics Inc fka NVLNF

[First Crown Research]

Parent company itself didn't file for bk, their sub did. Shareholders of the parent get to keep the cash there (which is not much but still), NOL's, and the nasdaq listing. Most importantly their intercompany loan claim with Aegion has been upheld which was 34m, and has been involved with the restructuring agreement giving shareholders about 8% of the new co, or 84% of the initial claim ie 30m.... Whitefort capital has been active in this name all along and has continued to buy post filing. trading at 15m now i only a little bit of it.